Oncotarget: Rapid onset type 1 diabetes with anti-PD-1 directed therapy

(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features 'Rapid onset type 1 diabetes with anti-PD-1 directed therapy', by Yun et al. and reported that Type 1 diabetes is a rare immune-related adverse event caused by checkpoint inhibitors with serious risk for diabetic ketoacidosis.